Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Etanercept’s New Autoinjection System; Plus FDA Approves Ixekizumab for Active PsA

  |  

In both studies, the primary efficacy endpoint was the proportion of patients achieving an ACR20 response at Week 24. Ixekizumab-treated patients achieved significant improvement in joint symptoms compared with placebo-treated patients. At Week 24 in the SPIRIT-P1 study, 58% of ixekizumab-treated patients compared with 30% of placebo-treated patients achieved ACR20. And in the SPRIT-P2 study, 53% of ixekizumab-treated patients compared with 20% of placebo-treated patients achieved ACR20.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Amgen Inc. Amgen launches the Enbril Mini single-dose, prefilled cartridge with AutoTouch reusable autoinjector that is ergonomically designed for patients. 2017 Nov. 17.
  2. Eli Lilly and Company. Lilly’s Taltz (ixekizumab) receives U.S. FDA approval for the treatment of active psoriatic arthritis. 2017 Dec 1.

Related Articles
    kenary820 / shutterstock.com

    Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

    Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    Ixekizumab Eases Psoriatic Arthritis when TNF Inhibitor Fails

    NEW YORK (Reuters Health)—The selective interleukin-17A inhibitor ixekizumab improved signs and symptoms of active psoriatic arthritis (PsA) in patients who had failed prior biologic therapy in the phase 3 SPIRIT-P2 trial. The SPIRIT-P2 trial joins the earlier phase 3 SPIRIT-P1 trial, which showed that ixekizumab was safe and effective in PsA patients not previously treated…

    Case Report: A Psoriatic Arthritis Patient with Dactylitis & Enthesitis

    A 36-year-old woman presented at the Johns Hopkins Arthritis Center for a second opinion regarding a diagnosis of psoriatic arthritis (PsA). One year prior to our evaluation, she had developed pain and stiffness in her hands, feet, knees, ankles, elbows and shoulders. She had mild plaque psoriasis of the scalp and base of the neck,…